Skip to content
  • Report Harm
  • Newsletter
  • Press Room
Facebook Linkedin YouTube Instagram Twitter Spotify
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • VolunteerExpand
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our ImpactExpand
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • ResourcesExpand
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Donate
Facebook Linkedin Twitter Instagram YouTube
Benzodiazepine Information Coalition

Short-Term Risks

Short term use are prescriptions lasting 2-4 weeks, including tapering off time, consecutively, or less. This method of prescribing is safer and aligned with guideline recommendations, but not without any risk.

Professor Sam Timimi, a consultant child and adolescent psychiatrist and director of postgraduate education in the NHS in Lincolnshire and a visiting professor of child and adolescent psychiatry at the University of Lincoln, points out why in this video: 

Even though they can be useful in the short-term, one of the big problems is – particularly in the way we think about what we’re doing when we’re prescribing drugs, psychiatric drugs – these days, is that even a short-term prescription can open the window towards a long-term one. Particularly if the prescriber is not aware of the potential for withdrawal symptoms, even after short-term prescriptions. What that can lead to is the prescriber confusing withdrawal symptoms with a return or even worsening of the original problem. And, from there, the window is opened towards a more long-term prescription rather than helping the person work through whatever withdrawal symptoms are occurring.

Also, even in short-term use, there are reports of people experiencing adverse effects (like paradoxical reactions) —sometimes severe ones—which are often misdiagnosed and “treated” with more drugs, leading to poly-drugging, expensive and invasive testing and often a prescription cascade. This is why, even if benzodiazepines are only used short term, it is so important that the medical community become fully aware of the risks and dangers so that they may quickly and accurately recognize and diagnose such things as resulting from the benzodiazepines before the patient is further harmed, misdiagnosed or improperly poly drugged.

There are many reports in of benzodiazepine harmed patients experiencing physically dependence in a very short time (less than 4 weeks) and/or who also reported experiencing tolerance, interdose, and subsequent withdrawal symptoms upon attempts at cessation even when the drugs were taken as prescribed for less than the recommended 4 weeks time.

Lastly, a meta-analysis published in May 2017 in the journal Clinical Pharmacist shows that fracture risk is highest among new users of both benzodiazepines and Z-drugs: 

Researchers carried out a systematic review and meta-analysis of studies involving benzodiazepines, Z-drugs and hip fracture risk. They identified 18 studies involving benzodiazepines and 6 involving Z-drugs. Compared with non-exposure, short-term use (up to 14 days) of benzodiazepines was associated with a 140% increased risk of hip fracture. medium-term use carried a 53% increased risk; and long-term use (>month) carried a 20% increased risk. For Z-drugs, short-term use was associated with a 139% increased risk of hip fracture and mixed-term use carried an 80% increased risk.

Additionally, the risks of benzodiazepines, at any length of time, has been found in studies to double the risk of car accidents. This outcome is consistent in many epidemiological studies.

Contact Us

Inquiries
bic@benzoinfo.com

As an awareness organization, we do not offer any support services or guidance. See our resources for services and support.

Mailing Address
1042 Ft. Union Blvd, PMB 1030
Midvale, Utah 84047

Support BIC

We were formed to change the lack of knowledge in the public and the medical system. But we cannot do it alone. We rely solely on donations to operate. We are a 501(c)(3) tax exempt organization.

DONATE

Newsletter

Get notified about the latest studies, updates, calls to action, media stories, and other information.

*

IMPORTANT: After signing up, check your email to confirm we have the correct address. If you do not see an email, check your spam. We will add you to our newsletter once you complete this step to ensure delivery.

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Privacy Policy
Medical Disclaimer
Terms and Conditions
Free Charity Hosting by Kualo

Facebook Linkedin YouTube Instagram Twitter Spotify

© 2023 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our Impact
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • Resources
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Search
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset